SCHEMBL19996345

SCHEMBL19996345

CC1(C)OB(c2ccc(C(O)O)cc2)OC1(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 13/20 0.53
LPL P06858 12/20 0.53
ESR2 Q92731 1/20 0.51
F11 P03951 2/20 0.47
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
CA9 Q16790 3/20 0.45
CA12 O43570 1/20 0.45
CA3 P07451 1/20 0.45
CA4 P22748 1/20 0.45
CA6 P23280 1/20 0.45
CA5A P35218 1/20 0.45
CA7 P43166 1/20 0.45
CA14 Q9ULX7 1/20 0.45
CA5B Q9Y2D0 1/20 0.45
P4HB P07237 1/20 0.42
F2 P00734 1/20 0.41
PRSS1 P07477 1/20 0.41
PRSS2 P07478 1/20 0.41
PRSS3 P35030 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14694622 0.86 LIPG (0.52) LIPGLPLESR2F11CA1
SCHEMBL24774874 0.86 LIPG (0.52) LIPGLPLESR2F11CA1
SCHEMBL24775237 0.86 LIPG (0.52) LIPGLPLESR2F11CA1
SCHEMBL25648947 0.85 LPL (0.50) LIPGLPLESR2F11CA1
SCHEMBL28371250 0.83 LIPG (0.57) LIPGLPLESR2F11CA1
SCHEMBL15774946 0.83 LIPG (0.49) LIPGLPLESR2F11CA1
SCHEMBL228212 0.82 LPL (0.71) LIPGLPLESR2F11CA1
SCHEMBL4508180 0.82 LPL (0.50) LIPGLPLESR2F11CA1
SCHEMBL31376528 0.82 ESR2 (0.50) LIPGLPLESR2F11CA1
SCHEMBL15774823 0.82 LPL (0.47) LIPGLPLESR2F11CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023110936-A1 REVERSIBLE MACROCYCLIC KINASE INHIBITORS NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) 2023-06-22 WO disclosed
US-9926314-B2 Compounds and compositions for the treatment of parasitic diseases NOVARTIS AG (CH) 2018-03-27 US disclosed